Found: 5
Select item for more details and to access through your institution.
Ibrutinib (Imbruvica) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 6, p. 1096, doi. 10.1007/s10637-014-0141-2
- By:
- Publication type:
- Article
Discovery of InsP<sub>6</sub>-kinases as InsP<sub>6</sub>-dephosphorylating enzymes provides a new mechanism of cytosolic InsP<sub>6</sub> degradation driven by the cellular ATP/ADP ratio.
- Published in:
- Biochemical Journal, 2014, v. 462, n. 1, p. 173, doi. 10.1042/BJ20130992
- By:
- Publication type:
- Article
Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
- Published in:
- International Journal of Cancer, 2013, v. 133, n. 9, p. 2065, doi. 10.1002/ijc.28214
- By:
- Publication type:
- Article
Downregulation of AKT3 Increases Migration and Metastasis in Triple Negative Breast Cancer Cells by Upregulating S100A4.
- Published in:
- PLoS ONE, 2016, v. 11, n. 1, p. 1, doi. 10.1371/journal.pone.0146370
- By:
- Publication type:
- Article
Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.
- Published in:
- Molecular Cancer, 2012, v. 11, n. 1, p. 85, doi. 10.1186/1476-4598-11-85
- By:
- Publication type:
- Article